Richard Mountfield
Consigliere Generale presso AURA BIOSCIENCES, INC.
Profilo
Richard Mountfield is currently working as the SVP-Regulatory Affairs & Quality at Aura Biosciences, Inc. Previously, he held positions as the VP-Global Regulatory Affairs at Celyad Oncology SA, Senior Vice President-Regulatory Affairs & Quality at Constellation Pharmaceuticals, Inc., and Senior VP-Regulatory Affairs & Drug Development at Boston Pharmaceuticals, Inc. In the future, he will be working as the SVP, Global Head-Regulatory Affairs & Quality at Zenas Pharma, Inc. Dr. Mountfield holds a doctorate degree from the University of Aberystwyth and an undergraduate degree from Coventry University.
Posizioni attive di Richard Mountfield
| Società | Posizione | Inizio |
|---|---|---|
| AURA BIOSCIENCES, INC. | Consigliere Generale | - |
Precedenti posizioni note di Richard Mountfield
| Società | Posizione | Fine |
|---|---|---|
Zenas Pharma, Inc.
 Zenas Pharma, Inc. BiotechnologyHealth Technology Zenas Pharma, Inc. is an American pharmaceutical company that is focused on developing a portfolio of first- and autoimmune therapeutics to address areas of high unmet medical need. The company is located in the US. The company's lead product candidate, obexelimab (zb012), is a novel bifunctional antibody with first-in-class potential that inhibits B-cell lineages that express CD19. | Consigliere Generale | 01/05/2023 |
| CONSTELLATION PHARMACEUTICALS, INC. | Consigliere Generale | 01/10/2021 |
Boston Pharmaceuticals, Inc.
 Boston Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Boston Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company that leverages a drug development team to advance a portfolio of high value candidates that address important unmet medical needs. The company was founded by Robert Armstrong and Chris Viehbacher and is headquartered in Cambridge, MA. | Consigliere Generale | 01/07/2020 |
| CELYAD ONCOLOGY SA | Consigliere Generale | - |
Formazione di Richard Mountfield
| University of Aberystwyth | Doctorate Degree |
| Coventry University | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 2 |
|---|---|
| CELYAD ONCOLOGY SA | Health Technology |
| AURA BIOSCIENCES, INC. | Health Technology |
| Aziende private | 3 |
|---|---|
Constellation Pharmaceuticals, Inc.
 Constellation Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Constellation Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapeutics in the field of epigenetics. The firm utilizes epigenetics platform, which enables to validate targets and generate small molecules against these targets that selectively modulate gene expression in tumor and immune cells to drive anti-tumor activity. Its product include CPI-0610, CPI-1205, and CPI-0209. The company was founded by Danny Reinberg, David Allis, and Yang Shi on January 11, 2008 and is headquartered in Cambridge, MA. | Health Technology |
Boston Pharmaceuticals, Inc.
Boston Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Boston Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company that leverages a drug development team to advance a portfolio of high value candidates that address important unmet medical needs. The company was founded by Robert Armstrong and Chris Viehbacher and is headquartered in Cambridge, MA. | Commercial Services |
Zenas Pharma, Inc.
Zenas Pharma, Inc. BiotechnologyHealth Technology Zenas Pharma, Inc. is an American pharmaceutical company that is focused on developing a portfolio of first- and autoimmune therapeutics to address areas of high unmet medical need. The company is located in the US. The company's lead product candidate, obexelimab (zb012), is a novel bifunctional antibody with first-in-class potential that inhibits B-cell lineages that express CD19. | Health Technology |
- Borsa valori
- Insiders
- Richard Mountfield
